Top section
Top section
◆ Crossover credit sells second senior SLB of 2026 ◆ Deal lands tight to secondaries and peers ◆ Proceeds to refinance 2028 convertible maturity
Company ‘made out like bandits’ as investors piled into deal and delta placement
Trade bodies speak out against push to drive equity trading on to lit markets
More articles
More articles
More articles
-
Alphamab Oncology, a Chinese biopharmaceutical firm, has launched a roadshow for an up to HK$1.83bn ($233.8m) listing, according to a source close to the deal. -
Senior managers and former employees of Future plc, one of the best performing companies on the London stockmarket, have sold £43.7m of stock in the company, via an accelerated bookbuild.
-
Surging equity markets and a spate of strong block sales have given equity investors a boost as they approach the end of the year.
-
Two senior French equity capital markets and coverage bankers who left Société Générale two months ago have joined arch-rival BNP Paribas.
-
Pharmaceutical research and development platform Pharmaron Beijing Co has bagged HK$4.6bn ($588m) after sealing its Hong Kong public offering at the top of the price guidance.
-
Hong Kong hosted Alibaba Group Holding’s jumbo IPO in tough political times this month, yet the deal received overwhelming support in primary and the shares soaring in the aftermarket. While this success gave the city’s stock market a much-needed boost, other issuers would be mistaken in thinking that such liquidity is also available to them.
Sub-sections
shared comment list
